Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer

Yan-zhi Chen; Zhan-dong Li; Fei Gao; ying Zhang; Hong Sun; Ping-ping Li

doi:10.1007/s11655-009-0415-2

Your Location：

Home >

Browse articles >

Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer

Updated：2021-08-27

- Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer
- Chinese Journal of Integrative Medicine Vol. 15, Issue 6, Pages: 415-419(2009)
- Affiliations：
  
  Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration Traditional Chinese and Western Medicine, Peking University School of Oncology, Beijing Cancer Hospital & Institute,Beijing,China
- Author bio：
- Funds：
  
  Supported by the Grant from Project of Beijing Traditional Chinese Medicine Bureau (No. JJ2001-12)
- DOI：10.1007/s11655-009-0415-2
  CLC：
- Published：2009，
  
  Published Online：18 January 2010，
Scan for full text
Chen, Yz., Li, Zd., Gao, F. et al. Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer., Chin. J. Integr. Med. 15, 415–419 (2009). https://doi.org/10.1007/s11655-009-0415-2

Yan-zhi Chen, Zhan-dong Li, Fei Gao, et al. Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 15(6):415-419(2009)
Chen, Yz., Li, Zd., Gao, F. et al. Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer., Chin. J. Integr. Med. 15, 415–419 (2009). https://doi.org/10.1007/s11655-009-0415-2 DOI：

Yan-zhi Chen, Zhan-dong Li, Fei Gao, et al. Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 15(6):415-419(2009) DOI： 10.1007/s11655-009-0415-2.

摘要

To evaluate the efficacy and side effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer (NSCLC). Sixty-three patients with stage III B and IV NSCLC hospitalized from October 2001 to October 2008 were enrolled and assigned to two groups using a randomizing digital table

with 33 patients in the treatment group and 30 in the control group. They were all treated with the Navelbine and Cisplatin (NP) chemotherapy

but to the treatment group the Chinese drugs Shengmai Injection (生脉注射液) by intravenous dripping and Gujin Granule (固金颗粒冲剂) by oral intake were given additionally. The main observation indexes were response rate (RR)

median survival time

1-year survival rate and median time to progression (TTP); secondary observation indexes were side effects and cycles of chemotherapy. Altogether

61 patients (33 from the treatment group and 28 from the control group) completed the observation and were assessable. RR was 48.5% (16/33) in the treatment group and 32.2% (9/28) in the control group

and the median survival time were 13 months and 9 months

respectively; the difference between the two groups was significant (P=0.0373 and P=0.014 respectively). However

the differences between groups were insignificant in terms of 1-year survival rate [51.5% (17/33) vs 46.4% (13/28)

P=0.4042]

median TTP (5.95 months vs 4.64 months

P=0.3242)

grade III or IV bone marrow inhibition occurrence rate [33.3% (11/33) vs 39.3% (11/28)

P=0.3500]

and mean cycles of chemotherapy applied (2.94±0.94 cycles vs 2.75±0.75 cycles

P=0.4100). Combined Chinese drugs and chemotherapy can enhance the short-term therapeutic efficacy in the treatment of NSCLC and prolong patients’ median survival time

but show no evident impact on TTP.

Abstract

with 33 patients in the treatment group and 30 in the control group. They were all treated with the Navelbine and Cisplatin (NP) chemotherapy

median survival time

1-year survival rate and median time to progression (TTP); secondary observation indexes were side effects and cycles of chemotherapy. Altogether

and the median survival time were 13 months and 9 months

respectively; the difference between the two groups was significant (P=0.0373 and P=0.014 respectively). However

the differences between groups were insignificant in terms of 1-year survival rate [51.5% (17/33) vs 46.4% (13/28)

P=0.4042]

median TTP (5.95 months vs 4.64 months

P=0.3242)

grade III or IV bone marrow inhibition occurrence rate [33.3% (11/33) vs 39.3% (11/28)

P=0.3500]

and mean cycles of chemotherapy applied (2.94±0.94 cycles vs 2.75±0.75 cycles

P=0.4100). Combined Chinese drugs and chemotherapy can enhance the short-term therapeutic efficacy in the treatment of NSCLC and prolong patients’ median survival time

but show no evident impact on TTP.

关键词

Chinese MedicineNavelbine and Cisplatin chemotherapyadvanced non-small cell lung cancerrandomized controlled

Keywords

Chinese MedicineNavelbine and Cisplatin chemotherapyadvanced non-small cell lung cancerrandomized controlled

references

Sun Y. The pathogenesis, prevention, early diagnosis and treatment for lung cancer. China Med Tribune 2004;30:13.

Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB–IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003;39:179–189.

Sun Y, ed. Medical oncology. Beijng: People’s Medical Publishing House; 2001:645–649.

Liu YX, Chen JH, eds. Internal medicine of traditional Chinese medicine. Beijng: People’s Medical Publishing House; 2001:77–80.

Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–4291.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.

Shen MH, Ruan SM, Lu N, Chen Z. Discussion on treating lung cancer based on supplementing qi and nourishing yin. Chin Arch Tradit Chin Med (Chin) 2009;27:254–256.

Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorebline and cisplatin versus vindesine and cisplatin versus vinorebline alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. Clin Oncol 1994;12:360–367.

Chen YZ, Li PP, Sun H, Guo QZ. Therapeutic effect of chemotherapy scheme relying mainly on navelbine in treatment of advanced non-small cell lung cancer. Chin J Clin Oncol (Chin) 2001;28:270–272.

Liu LS, Liu JX, Li CJ, Tian JH, Shi ZM. Clinical effect of Yiqi Yangyin Jiedu Decoction in treating patients with advanced non-small cell lung cancer. Chin J Integr Tradit West Med (Chin) 2008;28:352–355.

Cao Y, Yuan SH, Qiao ZB, Xiao L, Guo WW. Clinical study of Yiqi Yangyin Recipe combined with chemtheray in treating advanced non-small cell lung cancer. Chin J Basic Med Tradit Chin Med (Chin) 2003;9:32–33,35.

Wu MN, Liu XY, Fang J, Wang JJ, An TT. Vinorelbine combined with cisplatin in advanced stage non-small-cell lung cancer. China Oncol (Chin) 2004;14:184–186.

Lin HS. Clinical study of Chinese medicine in the management of advanced non-small cell lung cancer. In: Song SP, ed. Educational volume of China clinical oncology. Qingdao: China Ocean University Press; 2005:49–56.

Shu QJ, Wu LC. Experimental research on treatment of cancer with “Xinjiashashenmaidong Decoction”. Chin J Basic Med Tradit Chin Med (Chin) 2002;8:34–36.

Zhou DH, Lin LZ, Zhou YQ, Luo RC, Liu KF, Jia YJ, et al. Analysis of short-term therapeutic efficacy of integrated traditional and Western medicine in treating non-small cell lung cancer. Chin J Integr Tradit West Med (Chin) 2005;25:1061–1065.

FULL TEXT LINK

More>

Views

337

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Related Author

No data

Related Institution

Department of Traditional Chinese Medicine, Chinese People’s Liberation Army General Hospital

Department of Radiology, Chinese People’s Liberation Army General Hospital

Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Department of Integrative Oncology, Liaoning Cancer Hospital

Department of Traditional Chinese Medicine, Shanxi Cancer Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰